Investment fuels AI-driven development of breakthrough genomic medicines

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. Del Bourgo, Tom Gibbs (investment director, Debiopharm Innovation Fund), and Renaud Poulard (partner, venture capital, Omnes Capital) spoke with pharmaphorum about the organisation’s recent $10 million Series A fundraiser – led by Debiopharm Innovation Fund and Omnes Capital – and how Whitelab Genomics will use the capital to advance genomic medicine.


Read more